what do doctors think about biosimilars?
TRANSCRIPT
What Do Doctors Think About Biosimilars?
Powered by Small World Social
www.biolink.us
In March 2015, the Alliance for Safe Biologic Medicines (ASBM), released results from their survey of 400 US physicians on biologics medicines labeling.
Powered by Small World Social
www.biolink.us
The web-based survey was conducted before the FDA approved Zarxio, the first biosimilar in the US, and sought the view of dermatologists, endocrinologists, oncologists, nephrologists, neurologists and rheumatologists.
It found…Powered by Small World Social
www.biolink.us
Powered by Small World Social
considered it important for a
biosimilar’s product label to
clearly indicate that it is a
biosimilar.
90% of correspondents
4Biolink.us
Powered by Small World Social
it important for the
biosimilar label to include
the biosimilar sponsor’s
analytical data
demonstrating its analytical
similarity to the reference
product
82% thought
5Biolink.us
Powered by Small World Social
It important that the
biosimilar label includes the
clinical data, if any,
submitted to the FDA by the
sponsor again demonstrating
that it is highly similar to the
reference product
83% thought
6Biolink.us
Powered by Small World Social
It important that the label
explicitly state that the
specific indications or
conditions of use approved
for the originator product
that are not approved for the
biosimilar product
79% found
7Biolink.us
In 2013, the ASBM also surveyed 470 European physicians, from the United Kingdom, France, Germany, Italy and Spain to gauge their views on non-proprietary naming of biological medicines.
Powered by Small World Social
www.biolink.us
The survey highlighted the lack of awareness about biosimilars amongst prescribing specialist physicians and the need for further education.
It found…
Powered by Small World Social
www.biolink.us
Powered by Small World Social
said they are ‘familiar’ with
biosimilars, but only have a
basic understanding
54% of respondents
10Biolink.us
Powered by Small World Social
were unable to define
biosimilars
20% of the physicians
11Biolink.us
Powered by Small World Social
had never heard of
biosimilars
4% of respondents
12Biolink.us
Powered by Small World Social
were ‘very familiar’, with a
complete understanding of
biosimilars
22% of the physicians
13Biolink.us
Meanwhile, a study conducted by the Tufts Center of the Study of Drug Development, at Tufts University in Boston, found that…
Powered by Small World Social
www.biolink.us
Powered by Small World Social
While the majority of physicians, 70%, surveyed said they would be likely to prescribe biosimilars to a new patient, the overall lack of familiarity with the new products among specialist physicians could slow the uptake of biosimilars in the U.S.
15Biolink.us
Powered by Small World Social
www.biolink.us
Want to read more about biosimilars?
Visit:https://www.smallworldsocial.com/biolink/ to get the latest in biosimilar news curated from around the world